Last reviewed · How we verify
Connettivina 0.2% Cream
Connettivina 0.2% Cream is a Small molecule drug developed by Istituto Ganassini S.p.A. di Ricerche Biochimiche. It is currently in Phase 1 development.
At a glance
| Generic name | Connettivina 0.2% Cream |
|---|---|
| Sponsor | Istituto Ganassini S.p.A. di Ricerche Biochimiche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Connettivina 0.2% Cream CI brief — competitive landscape report
- Connettivina 0.2% Cream updates RSS · CI watch RSS
- Istituto Ganassini S.p.A. di Ricerche Biochimiche portfolio CI
Frequently asked questions about Connettivina 0.2% Cream
What is Connettivina 0.2% Cream?
Connettivina 0.2% Cream is a Small molecule drug developed by Istituto Ganassini S.p.A. di Ricerche Biochimiche.
Who makes Connettivina 0.2% Cream?
Connettivina 0.2% Cream is developed by Istituto Ganassini S.p.A. di Ricerche Biochimiche (see full Istituto Ganassini S.p.A. di Ricerche Biochimiche pipeline at /company/istituto-ganassini-s-p-a-di-ricerche-biochimiche).
What development phase is Connettivina 0.2% Cream in?
Connettivina 0.2% Cream is in Phase 1.